Hostname: page-component-8448b6f56d-sxzjt Total loading time: 0 Render date: 2024-04-23T23:29:06.064Z Has data issue: false hasContentIssue false
  • English
  • Français

A novel MYBPC3 c.2737+1 (IVS26) G>T mutation responsible for high-risk hypertrophic cardiomyopathy

Published online by Cambridge University Press:  21 November 2019

Wuyang Tong Open the ORCID record for Wuyang Tong [Opens in a new window] ,
Wei Liu ,
Hong Guo ,
Jiang Wang ,
Shiyong Yu ,
Jihang Zhang ,
Chuan Liu ,
Jia Chen  and
Xiaohui Zhao
Wuyang Tong
Affiliation:
Institute of Cardiovascular Diseases, Xinqiao Hospital, Army Medical University, Chongqing, China
Wei Liu
Affiliation:
Institute of Immunology, Army Medical University, Chongqing, China
Hong Guo
Affiliation:
Department of Medical Genetics, College of Basic Medical Science, Army Medical University, Chongqing, China
Jiang Wang
Affiliation:
Institute of Cardiovascular Diseases, Xinqiao Hospital, Army Medical University, Chongqing, China
Shiyong Yu
Affiliation:
Institute of Cardiovascular Diseases, Xinqiao Hospital, Army Medical University, Chongqing, China
Jihang Zhang
Affiliation:
Institute of Cardiovascular Diseases, Xinqiao Hospital, Army Medical University, Chongqing, China
Chuan Liu
Affiliation:
Institute of Cardiovascular Diseases, Xinqiao Hospital, Army Medical University, Chongqing, China
Jia Chen
Affiliation:
Department of Radiology, Xinqiao Hospital, Army Medical University, Chongqing, China
Xiaohui Zhao*
Affiliation:
Institute of Cardiovascular Diseases, Xinqiao Hospital, Army Medical University, Chongqing, China
*
Author for correspondence: X. Zhao, MD, Institute of Cardiovascular Research, Xinqiao Hospital, Army Medical University, 183 Xinqiao Road, Shapingba District, Chongqing 400037, China. Tel: +8613508332848. E-mail: doctorzhaoxiaohui@yahoo.com
Get access Rights & Permissions [Opens in a new window]

Abstract

Background:

Hypertrophic cardiomyopathy is an autosomal dominant hereditary disease characterised by left ventricular asymmetry hypertrophy. However, our knowledge of the genetic background in hypertrophic cardiomyopathy cases is limited. Here, we aimed to evaluate pathogenic gene mutations in a family with high-risk hypertrophic cardiomyopathy and analyse the genotype/phenotype relationships in this family.

Methods:

The proband, her parents, and her niece underwent whole-exome sequencing, and the genotypes of family members were identified using Sanger sequencing. mRNA expression was detected using reverse transcription sequencing. Structural impairments were predicted by homologous modelling. A family survey was conducted for patients with positive results to obtain information on general clinical symptoms, electrocardiography, ambulatory electrocardiography, echocardiography, and 3.0T cardiac magnetic resonance findings. Regular follow-up was performed for up to 6 months.

Results:

Five family members, including the proband, carried a cleavage site mutation in the MYBPC3 gene (c.2737+1 (IVS26) G>T), causing exon 26 of the MYBPC3 gene transcript to be skipped and leading to truncation of cardiac myosin-binding protein C. Family survey showed that the earliest onset age was 13 years old, and three people had died suddenly at less than 40 years old. Three pathogenic gene carriers were diagnosed with hypertrophic cardiomyopathy, and all showed severe ventricular septal hypertrophy.

Conclusion:

The c.2737+1 (IVS26) G>T mutation in the MYBPC3 gene led to exon 26 skipping, thereby affecting the structure and function of cardiac myosin-binding protein C and leading to severe ventricular hypertrophy and sudden death.

Keywords

Hypertrophic cardiomyopathyMYBPC3 genegenotypephenotype
Type
Original Article
Information
Cardiology in the Young , Volume 30 , Issue 1 , January 2020 , pp. 100 - 106
Copyright
© Cambridge University Press 2019

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Spirito, P, Autore, C, Formisano, F, et al. Risk of sudden death and outcome in patients with hypertrophic cardiomyopathy with benign presentation and without risk factors. Am J Cardiol 2014; 113: 1550–1555.CrossRefGoogle ScholarPubMed
Veselka, J, Zemánek, D, Jahnlová, D, et al. Risk and causes of death in patients after alcohol septal ablation for hypertrophic obstructive cardiomyopathy. Can J Cardiol 2015; 31: 1245–1251.CrossRefGoogle ScholarPubMed
Maron, BJ, Rowin, EJ, Casey, SA, et al. Hypertrophic cardiomyopathy in adulthood associated with low cardiovascular mortality with contemporary management strategies. J Am Coll Cardiol 2015; 65: 1915–1928.CrossRefGoogle ScholarPubMed
Pascoe, SJ. Clinical course and management of hypertrophic cardiomyopathy. N Engl J Med 2018; 379: 1976–1977.Google ScholarPubMed
Walsh, R, Buchan, R, Wilk, A, et al. Defining the genetic architecture of hypertrophic cardiomyopathy: re-evaluating the role of non-sarcomeric genes. Eur Heart J 2017; 38: 3461–3468.Google ScholarPubMed
Walsh, R, Thomson, KL, Ware, JS, et al. Reassessment of Mendelian gene pathogenicity using 7,855 cardiomyopathy cases and 60,706 reference samples. Genet Med 2017; 19: 192–203.CrossRefGoogle ScholarPubMed
Akhtar, M, Elliott, P. The genetics of hypertrophic cardiomyopathy. Glob Cardiol Sci Pract 2018; 2018: 36.Google ScholarPubMed
Marian, AJ, Braunwald, E. Hypertrophic cardiomyopathy: genetics, pathogenesis, clinical manifestations, diagnosis, and therapy. Circ Res 2017; 121: 749–770.CrossRefGoogle ScholarPubMed
Liew, AC, Vassiliou, VS, Cooper, R, Raphael, CE. Hypertrophic cardiomyopathy-past, present and future. J Clin Med 2017; 6: 118.CrossRefGoogle ScholarPubMed
Bamshad, MJ, Ng, SB, Bigham, AW, et al. Exome sequencing as a tool for Mendelian disease gene discovery. Nat Rev Genet 2011; 12: 745–755.CrossRefGoogle ScholarPubMed
Leproust, E. Target enrichment strategies for next generation sequencing. Mlo Med Lab Obs 2012; 44: 26–27.Google ScholarPubMed
Petersen, BS, Fredrich, B, Hoeppner, MP, Ellinghaus, D, Franke, A. Opportunities and challenges of whole-genome and -exome sequencing. BMC Genet 2017; 18: 14.CrossRefGoogle ScholarPubMed
Rayment, I, Holden, HM, Sellers, JR, Fananapazir, L, Epstein, ND. Structural interpretation of the mutations in the beta-cardiac myosin that have been implicated in familial hypertrophic cardiomyopathy. Proc Natl Acad Sci U S A 1995; 92: 3864–3868.CrossRefGoogle ScholarPubMed
Woo, A, Rakowski, H, Liew, JC, et al. Mutations of the beta myosin heavy chain gene in hypertrophic cardiomyopathy: critical functional sites determine prognosis. Heart 2003; 89: 1179–1185.CrossRefGoogle ScholarPubMed
Elliott, PM, Anastasakis, A, Borger, MA, et al. 2014 ESC guidelines on diagnosis and management of hypertrophic cardiomyopathy: the task force for the diagnosis and management of hypertrophic cardiomyopathy of the European Society of Cardiology (ESC). Eur Heart J 2014; 35: 2733–2779.Google Scholar
Richards, S, Aziz, N, Bale, S, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American college of medical genetics and genomics and the association for molecular pathology. Genet Med 2015; 17: 405–424.CrossRefGoogle ScholarPubMed
Carrier, L, Mearini, G, Stathopoulou, K, Cuello, F. Cardiac myosin-binding protein C (MYBPC3) in cardiac pathophysiology. Gene 2015; 573: 188–197.CrossRefGoogle Scholar
Sakamoto, N, Kawamura, Y, Sato, N, et al. Late gadolinium enhancement on cardiac magnetic resonance represents the depolarizing and repolarizing electrically damaged foci causing malignant ventricular arrhythmia in hypertrophic cardiomyopathy. Heart Rhythm 2015; 12: 1276–1284.CrossRefGoogle ScholarPubMed
Charron, P, Dubourg, O, Desnos, M, et al. Clinical features and prognostic implications of familial hypertrophic cardiomyopathy related to the cardiac myosin-binding protein C gene. Circulation 1998; 97: 2230–2236.CrossRefGoogle ScholarPubMed
Niimura, H, Bachinski, LL, Sangwatanaroj, S, et al. Mutations in the gene for cardiac myosin-binding protein C and late-onset familial hypertrophic cardiomyopathy. N Engl J Med 1998; 338: 1248–1257.CrossRefGoogle ScholarPubMed
Erdmann, J, Raible, J, Maki-Abadi, J, et al. Spectrum of clinical phenotypes and gene variants in cardiac myosin-binding protein C mutation carriers with hypertrophic cardiomyopathy. J Am Coll Cardiol 2001; 38: 322–330.CrossRefGoogle ScholarPubMed
Gilbert, R, Kelly, MG, Mikawa, T, Fischman, DA. The carboxyl terminus of myosin binding protein C (MyBP-C, C-protein) specifies incorporation into the A-band of striated muscle. J Cell Sci 1996; 109 (Pt 1): 101–111.Google ScholarPubMed
Gilbert, R, Cohen, JA, Pardo, S, Basu, A, Fischman, DA. Identification of the A-band localization domain of myosin binding proteins C and H (MyBP-C, MyBP-H) in skeletal muscle. J Cell Sci 1999; 112 (Pt 1): 69–79.Google Scholar
Freiburg, A, Gautel, M. A molecular map of the interactions between titin and myosin-binding protein C. Implications for sarcomeric assembly in familial hypertrophic cardiomyopathy. Eur J Biochem 1996; 235: 317–323.CrossRefGoogle ScholarPubMed
Monteiro, DRA, Guerrero-Serna, G, Helms, A, et al. Deficient cMyBP-C protein expression during cardiomyocyte differentiation underlies human hypertrophic cardiomyopathy cellular phenotypes in disease specific human ES cell derived cardiomyocytes. J Mol Cell Cardiol 2016; 99: 197–206.CrossRefGoogle Scholar
Prondzynski, M, Mearini, G, Carrier, L. Gene therapy strategies in the treatment of hypertrophic cardiomyopathy. Pflugers Arch 2019; 471: 807–815.CrossRefGoogle ScholarPubMed
Hammond, SM, Wood, MJ. Genetic therapies for RNA mis-splicing diseases. Trends Genet 2011; 27: 196–205.CrossRefGoogle ScholarPubMed
Gedicke-Hornung, C, Behrens-Gawlik, V, Reischmann, S, et al. Rescue of cardiomyopathy through U7snRNA-mediated exon skipping in Mybpc3-targeted knock-in mice. Embo Mol Med 2013; 5: 1128–1145.CrossRefGoogle ScholarPubMed
Garcia-Giustiniani, D, Arad, M, Ortiz-Genga, M, et al. Phenotype and prognostic correlations of the converter region mutations affecting the beta myosin heavy chain. Heart 2015; 101: 1047–1053.CrossRefGoogle ScholarPubMed
Supplementary material: File

Tong et al. supplementary material

Tong et al. supplementary material 1

Download Tong et al. supplementary material(File)
File 17.8 KB
Supplementary material: File

Tong et al. supplementary material

Tong et al. supplementary material 2

Download Tong et al. supplementary material(File)
File 15.4 KB
Supplementary material: Image

Tong et al. supplementary material

Tong et al. supplementary material 3

Download Tong et al. supplementary material(Image)
Image 5 MB